Drug Profile
Laromustine - Vion Pharmaceuticals
Alternative Names: 101M; Cloretazine; Onrigin; VNP 4010M; VNP40101MLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Yale University
- Developer Vion Pharmaceuticals
- Class Antineoplastics; Hydrazines; Small molecules; Sulfonamides
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Acute myeloid leukaemia; Glioma; Myelodysplastic syndromes
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 27 Aug 2018 Vion Pharmaceuticals terminates a phase I/II trial for Myelodysplastic syndromes and Acute myeloid leukaemia (In the elderly, Combination therapy) in USA (IV) (NCT00655395)
- 27 Feb 2010 Vion receives an FDA response relating to the SPA for the phase II/III trial in Acute myeloid leukaemia
- 13 Jan 2010 Vion files a Special Protocol Assessment for a phase II//III trial of laromustine in combination with low-dose Ara-C in elderly patients with newly diagnosed Acute myeloid leukaemia in USA